Advertisement

Bioinformatics identification of key candidate genes and pathways associated with systemic lupus erythematosus

  • Fangyuan Yang
  • Zeqing Zhai
  • Xiaoqing Luo
  • Guihu Luo
  • Lili Zhuang
  • Yanan Zhang
  • Yehao Li
  • Erwei SunEmail author
  • Yi HeEmail author
Original Article

Abstract

Objective

Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by autoantibody production and multi-system involvement, but the etiology is largely unclear. This study aimed to elucidate candidate genes and pathways involved in SLE.

Methods

Three original datasets GSE72509, GSE20864, and GSE39088 were downloaded from Gene Expression Omnibus (GEO) and the data were further integrated and analyzed. Subsequently, differentially expressed genes (DEGs) between SLE patients and healthy people were identified. And then we performed gene ontology (GO) function and pathway enrichment analyses of common DEGs, and constructed a protein-protein interaction (PPI) network with STRING database. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was carried out to validate the expression levels of candidate genes in blood samples from SLE patients and healthy controls.

Results

In total, 321 common DEGs were identified in SLE patients compared with healthy controls, including 231 upregulated and 90 downregulated genes. GO function analysis revealed that 321 common DEGs were mainly enriched in innate immune response, defense response, cytokine-mediated signaling pathway, response to interferon-alpha, and I-kappaB kinase/NF-kappaB signaling. Additionally, pathway enrichment analysis indicated that DEGs were mainly enriched in several signaling pathways associated with immune system and apoptosis, including RIG-I-like receptor signaling pathway, antigen processing and presentation, and p53 signaling pathway. The expression levels of candidate genes RPL26L1, FBXW11, FOXO1, and SMAD7 were validated by RT-qPCR analysis.

Conclusions

The four hub genes including RPL26L1, FBXW11, FOXO1, and SMAD7 may play key roles in the pathogenesis and development of SLE. RIG-I-like receptor signaling pathway, antigen processing and presentation pathway, and p53 signaling pathway may be closely implicated in SLE pathogenesis. Collectively, these results may provide valuable novel markers or targets for the diagnosis and treatment of SLE.

Key Points

• Integrated bioinformatics analysis of three profile datasets based on SLE patients and healthy controls was performed and 321 common DEGs were identified.

• The 321 common DEGs were mainly enriched in biological processes related to immune responses and inflammatory responses, including innate immune response, defense response, cytokine-mediated signaling pathway, response to interferon-alpha, I-kappaB kinase/NF-kappaB signaling, whereas the three most significant cellular components were oxidoreductase complex, AIM2 inflammasome complex, and ubiquitin ligase complex.

• KEGG pathway enrichment analysis indicated that common DEGs were mainly enriched in several signaling pathways associated with immune system and apoptosis, including RIG-I-like receptor signaling pathway, antigen processing and presentation, and p53 signaling pathway.

• Candidate genes RPL26L1, FBXW11, FOXO1, and SMAD7 may be closely involved in the pathogenesis and development of SLE and may provide valuable novel markers or targets for the diagnosis and treatment of SLE.

Keywords

Bioinformatics analysis Interferon signaling pathway NF-κB signaling pathway RIG-I-like receptor signaling pathway Systemic lupus erythematosus 

Notes

Acknowledgments

We gratefully thank many researchers for providing technical assistance and all the patients who were enrolled in the study.

Funding information

This work was supported by grants from National Natural Science Foundation of China (No. 81501417, No. 81671623) and Science and Technology Planning Project of Guangdong Province, China (2014B020212024).

Compliance with ethical standards

Declaration of conflicting interests

The authors declare that there is no conflict of interest.

Ethics approval and consent to participate

The study was approved by the Ethics Committee of The Third Affiliated Hospital of Southern Medical University. Informed consent has been obtained from the patients’ legal guardians.

Supplementary material

10067_2019_4751_MOESM1_ESM.docx (28 kb)
ESM 1 (DOCX 27 kb)

References

  1. 1.
    Tsokos GC (2011) Systemic lupus erythematosus. N Engl J Med 365:2110–2121.  https://doi.org/10.1056/NEJMra1100359 CrossRefPubMedGoogle Scholar
  2. 2.
    Carter EE, Barr SG, Clarke AE (2016) The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol 12:605–620.  https://doi.org/10.1038/nrrheum.2016.137 CrossRefPubMedGoogle Scholar
  3. 3.
    Ohl K, Tenbrock K (2015) Regulatory T cells in systemic lupus erythematosus. Eur J Immunol 45:344–355.  https://doi.org/10.1002/eji.201344280 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Moulton VR, Tsokos GC (2015) T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity. J Clin Investig 125:2220–2227.  https://doi.org/10.1172/JCI78087 CrossRefPubMedGoogle Scholar
  5. 5.
    Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL (2001) Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 159:237–243CrossRefGoogle Scholar
  6. 6.
    Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 100:2610–2615.  https://doi.org/10.1073/pnas.0337679100 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Le Bon A, Durand V, Kamphuis E, Thompson C, Bulfone-Paus S, Rossmann C et al (2006) Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming. J Immunol 176:4682–4689CrossRefGoogle Scholar
  8. 8.
    Swanson CL, Wilson TJ, Strauch P, Colonna M, Pelanda R, Torres RM (2010) Type I IFN enhances follicular B cell contribution to the T cell-independent antibody response. J Exp Med 207:1485–1500.  https://doi.org/10.1084/jem.20092695 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Xu HC, Grusdat M, Pandyra AA, Polz R, Huang J, Sharma P, Deenen R, Köhrer K, Rahbar R, Diefenbach A, Gibbert K, Löhning M, Höcker L, Waibler Z, Häussinger D, Mak TW, Ohashi PS, Lang KS, Lang PA (2014) Type I interferon protects antiviral CD8+ T cells from NK cell cytotoxicity. IMMUNITY. 40:949–960.  https://doi.org/10.1016/j.immuni.2014.05.004 CrossRefPubMedGoogle Scholar
  10. 10.
    Donnelly S, Roake W, Brown S, Young P, Naik H, Wordsworth P, Isenberg DA, Reid KBM, Eggleton P (2006) Impaired recognition of apoptotic neutrophils by the C1q/calreticulin and CD91 pathway in systemic lupus erythematosus. Arthritis Rheum 54:1543–1556.  https://doi.org/10.1002/art.21783 CrossRefPubMedGoogle Scholar
  11. 11.
    Jorch SK, Kubes P (2017) An emerging role for neutrophil extracellular traps in noninfectious disease. Nat Med 23:279–287.  https://doi.org/10.1038/nm.4294 CrossRefPubMedGoogle Scholar
  12. 12.
    Hung T, Pratt GA, Sundararaman B, Townsend MJ, Chaivorapol C, Bhangale T, Graham RR, Ortmann W, Criswell LA, Yeo GW, Behrens TW (2015) The Ro60 autoantigen binds endogenous retroelements and regulates inflammatory gene expression. SCIENCE. 350:455–459.  https://doi.org/10.1126/science.aac7442 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Lee HM, Sugino H, Aoki C, Nishimoto N (2011) Underexpression of mitochondrial-DNA encoded ATP synthesis-related genes and DNA repair genes in systemic lupus erythematosus. Arthritis Res Ther 13:R63.  https://doi.org/10.1186/ar3317 CrossRefGoogle Scholar
  14. 14.
    Lauwerys BR, Hachulla E, Spertini F, Lazaro E, Jorgensen C, Mariette X, Haelterman E, Grouard-Vogel G, Fanget B, Dhellin O, Vandepapelière P, Houssiau FA (2013) Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid. Arthritis Rheum 65:447–456.  https://doi.org/10.1002/art.37785 CrossRefPubMedGoogle Scholar
  15. 15.
    Ducreux J, Houssiau FA, Vandepapeliere P, Jorgensen C, Lazaro E, Spertini F et al (2016) Interferon alpha kinoid induces neutralizing anti-interferon alpha antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon alpha kinoid phase I/II study. Rheumatology (Oxford) 55:1901–1905.  https://doi.org/10.1093/rheumatology/kew262 CrossRefGoogle Scholar
  16. 16.
    Xia J, Gill EE, Hancock RE (2015) NetworkAnalyst for statistical, visual and network-based meta-analysis of gene expression data. Nat Protoc 10:823–844.  https://doi.org/10.1038/nprot.2015.052 CrossRefPubMedGoogle Scholar
  17. 17.
    Li J, Wang F, Wang G, Sun Y, Cai J, Liu X, Zhang J, Lu X, Li Y, Chen M, Chen L, Jiang C (2017) Combination epidermal growth factor receptor variant III peptide-pulsed dendritic cell vaccine with miR-326 results in enhanced killing on EGFRvIII-positive cells. Oncotarget. 8:26256–26268.  https://doi.org/10.18632/oncotarget.15445 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Wu C, Zhao Y, Lin Y, Yang X, Yan M, Min Y, Pan Z, Xia S, Shao Q (2018) Bioinformatics analysis of differentially expressed gene profiles associated with systemic lupus erythematosus. Mol Med Rep 17:3591–3598.  https://doi.org/10.3892/mmr.2017.8293 CrossRefPubMedGoogle Scholar
  19. 19.
    Labonte AC, Kegerreis B, Geraci NS, Bachali P, Madamanchi S, Robl R, Catalina MD, Lipsky PE, Grammer AC (2018) Identification of alterations in macrophage activation associated with disease activity in systemic lupus erythematosus. PLoS One 13:e208132.  https://doi.org/10.1371/journal.pone.0208132 CrossRefGoogle Scholar
  20. 20.
    Tsokos GC, Lo MS, Costa RP, Sullivan KE (2016) New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol 12:716–730.  https://doi.org/10.1038/nrrheum.2016.186 CrossRefPubMedGoogle Scholar
  21. 21.
    Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS et al (2006) Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 54:2951–2962.  https://doi.org/10.1002/art.22044 CrossRefPubMedGoogle Scholar
  22. 22.
    Weidenbusch M, Kulkarni OP, Anders HJ (2017) The innate immune system in human systemic lupus erythematosus. Clin Sci (Lond) 131:625–634.  https://doi.org/10.1042/CS20160415 CrossRefGoogle Scholar
  23. 23.
    Dixit E, Kagan JC (2013) Intracellular pathogen detection by RIG-I-like receptors. Adv Immunol 117:99–125.  https://doi.org/10.1016/B978-0-12-410524-9.00004-9 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Kato H, Fujita T (2015) RIG-I-like receptors and autoimmune diseases. Curr Opin Immunol 37:40–45.  https://doi.org/10.1016/j.coi.2015.10.002 CrossRefPubMedGoogle Scholar
  25. 25.
    Wu C, Zhao Y, Lin Y, Yang X, Yan M, Min Y, Pan Z, Xia S, Shao Q (2017) Bioinformatics analysis of differentially expressed gene profiles associated with systemic lupus erythematosus. Mol Med Rep.  https://doi.org/10.3892/mmr.2017.8293
  26. 26.
    Brown KD, Claudio E, Siebenlist U (2008) The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther 10:212.  https://doi.org/10.1186/ar2457 CrossRefGoogle Scholar
  27. 27.
    Enzler T, Bonizzi G, Silverman GJ, Otero DC, Widhopf GF, Anzelon-Mills A, Rickert RC, Karin M (2006) Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity 25:403–415.  https://doi.org/10.1016/j.immuni.2006.07.010 CrossRefPubMedGoogle Scholar
  28. 28.
    Barnes PJ, Karin M (1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066–1071.  https://doi.org/10.1056/NEJM199704103361506 CrossRefPubMedGoogle Scholar
  29. 29.
    Baeuerle PA, Baichwal VR (1997) NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv Immunol 65:111–137CrossRefGoogle Scholar
  30. 30.
    Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, Xu W, Parrish-Novak J, Foster D, Lofton-Day C, Moore M, Littau A, Grossman A, Haugen H, Foley K, Blumberg H, Harrison K, Kindsvogel W, Clegg CH (2000) TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. NATURE. 404:995–999.  https://doi.org/10.1038/35010115 CrossRefPubMedGoogle Scholar
  31. 31.
    You Y, Qin Y, Lin X, Yang F, Li J, Sooranna SR, Pinhu L (2015) Methylprednisolone attenuates lipopolysaccharide-induced Fractalkine expression in kidney of Lupus-prone MRL/lpr mice through the NF-kappaB pathway. BMC Nephrol 16:148.  https://doi.org/10.1186/s12882-015-0145-y CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Hu Q, Yang C, Wang Q, Zeng H, Qin W (2015) Demethylzeylasteral (T-96) treatment ameliorates mice lupus nephritis accompanied by inhibiting activation of NF-kappaB pathway. PLoS One 10:e133724.  https://doi.org/10.1371/journal.pone.0133724 CrossRefGoogle Scholar
  33. 33.
    Qu H, Bian W, Xu Y (2014) A novel NF-kappaB inhibitor, DHMEQ, ameliorates pristane-induced lupus in mice. Exp Ther Med 8:100–104.  https://doi.org/10.3892/etm.2014.1718 CrossRefGoogle Scholar
  34. 34.
    Winston JT, Strack P, Beer-Romero P, Chu CY, Elledge SJ, Harper JW (1999) The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev 13:270–283CrossRefGoogle Scholar
  35. 35.
    Shi P, Zhu S, Lin Y, Liu Y, Liu Y, Chen Z, Shi Y, Qian Y (2011) Persistent stimulation with interleukin-17 desensitizes cells through SCFbeta-TrCP-mediated degradation of Act1. Sci Signal 4:a73.  https://doi.org/10.1126/scisignal.2001653 CrossRefGoogle Scholar
  36. 36.
    Li Y, Ma Z, Jiang S, Hu W, Li T, Di S et al (2017) A global perspective on FOXO1 in lipid metabolism and lipid-related diseases. Prog Lipid Res 66:42–49.  https://doi.org/10.1016/j.plipres.2017.04.002 CrossRefPubMedGoogle Scholar
  37. 37.
    Zhang X, Tang N, Hadden TJ, Rishi AK (2011) Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta 1813:1978–1986.  https://doi.org/10.1016/j.bbamcr.2011.03.010 CrossRefPubMedGoogle Scholar
  38. 38.
    Martins R, Lithgow GJ, Link W (2016) Long live FOXO: unraveling the role of FOXO proteins in aging and longevity. Aging Cell 15:196–207.  https://doi.org/10.1111/acel.12427 CrossRefPubMedGoogle Scholar
  39. 39.
    Vogt PK, Jiang H, Aoki M (2005) Triple layer control: phosphorylation, acetylation and ubiquitination of FOXO proteins. Cell Cycle 4:908–913.  https://doi.org/10.4161/cc.4.7.1796 CrossRefPubMedGoogle Scholar
  40. 40.
    Malik S, Sadhu S, Elesela S, Pandey RP, Chawla AS, Sharma D, Panda L, Rathore D, Ghosh B, Ahuja V, Awasthi A (2017) Transcription factor Foxo1 is essential for IL-9 induction in T helper cells. Nat Commun 8:815.  https://doi.org/10.1038/s41467-017-00674-6 CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Kuo CC, Lin SC (2007) Altered FOXO1 transcript levels in peripheral blood mononuclear cells of systemic lupus erythematosus and rheumatoid arthritis patients. Mol Med 13:561–566.  https://doi.org/10.2119/2007-00021.Kuo CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Omori SA, Cato MH, Anzelon-Mills A, Puri KD, Shapiro-Shelef M, Calame K, Rickert RC (2006) Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling. Immunity 25:545–557.  https://doi.org/10.1016/j.immuni.2006.08.015 CrossRefPubMedGoogle Scholar
  43. 43.
    Chen J, Yusuf I, Andersen HM, Fruman DA (2006) FOXO transcription factors cooperate with delta EF1 to activate growth suppressive genes in B lymphocytes. J Immunol 176:2711–2721CrossRefGoogle Scholar
  44. 44.
    Yusuf I, Zhu X, Kharas MG, Chen J, Fruman DA (2004) Optimal B-cell proliferation requires phosphoinositide 3-kinase-dependent inactivation of FOXO transcription factors. Blood 104:784–787.  https://doi.org/10.1182/blood-2003-09-3071 CrossRefPubMedGoogle Scholar
  45. 45.
    Laine A, Martin B, Luka M, Mir L, Auffray C, Lucas B et al (2015) Foxo1 is a T cell-intrinsic inhibitor of the RORgammat-Th17 program. J Immunol 195:1791–1803.  https://doi.org/10.4049/jimmunol.1500849 CrossRefPubMedGoogle Scholar
  46. 46.
    Liu L, Liu Y, Yuan M, Xu L, Sun H (2017) Elevated expression of microRNA-873 facilitates Th17 differentiation by targeting forkhead box O1 (Foxo1) in the pathogenesis of systemic lupus erythematosus. Biochem Biophys Res Commun 492:453–460.  https://doi.org/10.1016/j.bbrc.2017.08.075 CrossRefPubMedGoogle Scholar
  47. 47.
    Miyazawa K, Miyazono K. Regulation of TGF-beta family signaling by inhibitory Smads. Cold Spring Harb Perspect Biol 2017;9. doi:  https://doi.org/10.1101/cshperspect.a022095 CrossRefGoogle Scholar
  48. 48.
    Sole C, Gimenez-Barcons M, Ferrer B, Ordi-Ros J, Cortes-Hernandez J (2016) Microarray study reveals a transforming growth factor-beta-dependent mechanism of fibrosis in discoid lupus erythematosus. Br J Dermatol 175:302–313.  https://doi.org/10.1111/bjd.14539 CrossRefPubMedGoogle Scholar
  49. 49.
    Ka SM, Huang XR, Lan HY, Tsai PY, Yang SM, Shui HA, Chen A (2007) Smad7 gene therapy ameliorates an autoimmune crescentic glomerulonephritis in mice. J Am Soc Nephrol 18:1777–1788.  https://doi.org/10.1681/ASN.2006080901 CrossRefPubMedGoogle Scholar
  50. 50.
    Towers CG, Guarnieri AL, Micalizzi DS, Harrell JC, Gillen AE, Kim J, Wang CA, Oliphant MUJ, Drasin DJ, Guney MA, Kabos P, Sartorius CA, Tan AC, Perou CM, Espinosa JM, Ford HL (2015) The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p. Nat Commun 6:10077.  https://doi.org/10.1038/ncomms10077 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2019

Authors and Affiliations

  1. 1.Department of Rheumatology and ImmunologyThe Third Affiliated Hospital, Southern Medical UniversityGuangzhouChina
  2. 2.Institute of Clinical ImmunologyAcademy of Orthopedics, Guangdong ProvinceGuangzhouChina

Personalised recommendations